Life expectancy with aortic stenosis ranges from a couple of years to something close to a normal lifespan, and the single biggest factor determining where you land on that spectrum is whether and when you get the valve fixed. Left untreated, severe symptomatic aortic stenosis carries a grim prognosis: most patients die within two to three years of diagnosis. But a successful valve replacement in an otherwise healthy person can bring survival back in line with what you’d expect for someone of the same age without the disease. The gap between those two outcomes makes aortic stenosis a condition where the details matter enormously.
What Happens Without Treatment
The natural history of untreated aortic stenosis is one of the bleakest in cardiology. Once a person with severe stenosis starts having symptoms like chest pain, fainting, or breathlessness, the clock accelerates. A UK-based study of patients who did not undergo surgery described most dying within two to three years of diagnosis.1PubMed Central. Unoperated severe aortic stenosis: decision making in an adult UK-based population Older data from cohorts of elderly patients (age 80 and above) paints an even starker picture: five-year survival without valve replacement was only about 22%, compared with 68% in those who had the valve replaced.2European Journal of Cardio-Thoracic Surgery. Survival in elderly patients with severe aortic stenosis is dramatically improved by aortic valve replacement: results from a cohort of 277 patients aged ≥80 years
A large-scale study of nearly 600,000 patients with echocardiographic severity assessments put numbers on the full severity spectrum. Over four years without treatment, roughly one in four patients with mild stenosis died, about one in three with moderate stenosis died, and close to 45% of those with severe or moderate-to-severe stenosis died.3PubMed. The Mortality Burden of Untreated Aortic Stenosis That means even milder forms of the disease carry a measurable mortality burden, though the jump in risk from moderate to severe is where the real danger concentrates.
How Valve Replacement Changes the Picture
Aortic valve replacement, whether done through open-heart surgery (surgical AVR) or through a catheter threaded into the artery (transcatheter AVR, or TAVR), is the only treatment that meaningfully extends life in severe aortic stenosis. No medication has been shown to do the same. The question for most patients is not whether to get the valve replaced, but how much of a survival benefit to expect based on their individual risk profile.
A study tracking over 1,100 patients who underwent surgical AVR found that low-risk patients (based on a standard surgical risk score below 3%) had survival rates comparable to the age- and sex-matched general population across all age groups. Intermediate-risk patients under 75 did not fare quite as well as their peers without the disease, but those 75 and older with intermediate risk did match population-level survival.4PubMed. Life Expectancy of Patients With Severe Aortic Stenosis in Relation to Age and Surgical Risk Score High-risk patients had higher mortality than the general population regardless of age, which reflects the fact that “high risk” in this context usually means serious coexisting diseases.
A large Swedish registry study followed over 33,000 surgical AVR patients for an average of more than seven years. Roughly 43% died over that follow-up period, with cardiovascular causes accounting for the largest share. Compared with the general population, these patients had about 1.8 times the expected rate of cardiovascular death, while their cancer-related and other-cause mortality were essentially normal.5Journal of the American Heart Association. Cause of Death After Surgical Aortic Valve Replacement: SWEDEHEART Observational Study In other words, the valve surgery doesn’t perfectly erase the cardiovascular risk, but it neutralizes most of the excess danger from other causes.
Outcomes After TAVR
TAVR has transformed treatment for patients who are too frail or too old for open-heart surgery, and it is increasingly used in lower-risk patients too. A national registry study of over 6,000 TAVR patients (average age about 83) reported overall five-year survival of 70% and ten-year survival of 42%.6PubMed Central. Contemporary Life Expectancy Following Transfemoral Transcatheter Aortic Valve Replacement-Data From a National Registry Perspective Among younger patients in that registry (under 80), eight-year survival in more recent treatment eras reached 82%, a substantial improvement over earlier periods.
A retrospective cohort study found TAVR survival rates of about 95% at one year, 79% at four years, and 54% at seven years. Being younger than 85 and having the catheter inserted through the leg artery (the transfemoral approach) were both associated with better outcomes, while kidney disease, cerebrovascular disease, and connective tissue disease predicted poorer survival.7Scientific Reports. Long-term survival evaluation after transcatheter aortic valve implantation in patients with severe aortic valve stenosis: a retrospective cohort study
When comparing the two approaches head to head, a Japanese study found that low-risk patients who had surgical AVR achieved five-year survival comparable to the general population (about 90%), whereas low- and intermediate-risk patients who had TAVR fell somewhat short of their population-matched peers.8Journal of Cardiology. Long-term survival after surgical or transcatheter aortic valve replacement for low or intermediate surgical risk aortic stenosis: Comparison with general population This gap likely reflects TAVR patients being older and sicker on average, plus uncertainty about how transcatheter valves hold up over very long follow-up. For patients in their seventies and eighties who cannot safely undergo open-heart surgery, TAVR still offers a dramatic survival advantage over no treatment at all.
How Fast Does Aortic Stenosis Get Worse?
Aortic stenosis is a progressive disease, and the speed of progression matters because it determines how quickly a mild case becomes a severe one. A meta-analysis found that, on average, the valve opening area shrinks by about 0.08 square centimeters per year, and patients who start with more advanced stenosis tend to progress faster.9PubMed. Aortic Stenosis Progression: A Systematic Review and Meta-Analysis Another study reported a similar median shrinkage of 0.09 square centimeters per year, though individual patients varied widely.10PubMed Central. Prediction of the Individual Aortic Stenosis Progression Rate and its Association With Clinical Outcomes
Several factors appear to accelerate the narrowing. Kidney disease, diabetes, high LDL cholesterol, and the degree of calcium already built up on the valve all predict faster progression.11PubMed Central. Risk factors for progression of calcific aortic stenosis and potential therapeutic targets One study found a strong link between LDL cholesterol levels and the rate of aortic valve calcification, raising the natural question of whether statins could slow the disease down.12PubMed. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors The answer to that question, as it turned out, was disappointing.
Why No Drug Slows the Disease
Despite the overlap between aortic stenosis risk factors and those for atherosclerosis, no medication has been proven to stop or slow the progression of the valve narrowing itself. A meta-analysis of 14 studies found that statins reliably lowered LDL cholesterol in aortic stenosis patients but had no significant effect on valve calcification, valve function, the need for valve replacement, or death from any cause.13Atherosclerosis. Impact of statins on aortic stenosis: A meta-analysis A state-of-the-art review in the Journal of the American College of Cardiology confirmed that despite numerous promising therapeutic targets, no proven medical treatment for calcific aortic stenosis exists.14PubMed Central. Evaluating Medical Therapy for Calcific Aortic Stenosis: JACC State-of-the-Art Review
That said, medications still play an important role after valve replacement. A large Swedish registry study found that patients who continued taking statins and blood-pressure-lowering drugs (specifically renin-angiotensin system inhibitors) after surgical AVR had lower long-term mortality than those who did not. Statin use was associated with about a third lower risk of death, and the association held across age groups, sexes, and comorbidity profiles.15PubMed Central. Associations between medical therapy after surgical aortic valve replacement for aortic stenosis and long-term mortality: a report from the SWEDEHEART registry So while statins cannot save the valve, they appear to help protect the patient’s cardiovascular system after the valve has been replaced.
The Asymptomatic Dilemma
One of the trickiest clinical decisions in aortic stenosis involves people whose echocardiogram shows a severely narrowed valve but who feel fine. Traditional guidelines have recommended watching and waiting until symptoms appear, but mounting evidence suggests that in certain patients, earlier surgery yields better results. A meta-analysis found that early valve replacement was associated with roughly 70-75% lower odds of dying compared with conservative management.16PubMed. Early intervention or watchful waiting for asymptomatic severe aortic valve stenosis: a systematic review and meta-analysis Another meta-analysis focusing specifically on study-level data reported a similar direction of benefit.17Structural Heart. Early Aortic Valve Replacement versus Watchful Waiting in Asymptomatic Severe Asymptomatic Severe Aortic Stenosis: A Study-Level Meta-Analysis
The picture is not entirely simple, though. A Japanese study found no significant survival difference between early surgery and surgery-after-watchful-waiting in asymptomatic severe aortic stenosis patients overall. Where the difference emerged was in a subgroup with very high flow velocities across the valve (4.5 meters per second or higher at diagnosis). In those patients, early surgery produced clearly better five-year survival, about 88% versus 71%.18PubMed. Early Surgery vs. Surgery After Watchful Waiting for Asymptomatic Severe Aortic Stenosis This suggests that the benefit of operating before symptoms appear may be concentrated in people whose disease is already advancing rapidly.
The Sudden Death Risk
One fear that hangs over the watchful-waiting approach is sudden cardiac death. In patients with severe symptomatic aortic stenosis, the five-year cumulative incidence of sudden death was about 9%. Among asymptomatic patients, it was lower but not negligible at about 7%, translating to roughly 1.4% per year. Two-thirds of those sudden deaths in asymptomatic patients occurred without any preceding symptoms, and most happened within three months of the last clinical checkup.19PubMed Central. Sudden Death in Patients With Severe Aortic Stenosis: Observations From the CURRENT AS Registry Risk factors included being on dialysis, prior heart attack, very high jet velocities, and reduced heart pumping function.
In a European cohort that tracked asymptomatic patients across the full spectrum of stenosis severity, the annualized sudden-death rate was lower, roughly 0.4% per year. Even after progression to severe stenosis, the rate only rose to 0.6% per year. In that study, older age, higher heart-muscle mass, and lower body mass index were the independent predictors.20PubMed. Sudden cardiac death in asymptomatic patients with aortic stenosis These numbers are low enough that watchful waiting remains a reasonable strategy for many asymptomatic patients, but they are not zero, which is part of why the push toward earlier intervention has been gaining ground.
Frailty Matters More Than You Might Think
Surgical risk scores calculate the chance of dying during or soon after surgery based on age, kidney function, lung disease, and similar factors. But frailty, a broader measure of how physically resilient a person is, often predicts outcomes better than any single lab value. In one study, frail patients had 3.5 times the one-year mortality after TAVR compared with non-frail patients, even after accounting for other risk factors.21PubMed Central. The impact of frailty status on survival after transcatheter aortic valve replacement in older adults with severe aortic stenosis: a single-center experience
A more recent study using a hospital-based frailty scoring system found a clear stepwise relationship: two-year survival after TAVR in late-elderly patients was about 89% for those with low frailty scores, 83% for intermediate, and 68% for high frailty scores.22PubMed Central. Impact of the Hospital Frailty Risk Score on Outcomes After Transcatheter Aortic Valve Replacement in Late Elderly Patients Beyond frailty itself, specific noncardiac conditions have outsized effects. Advanced kidney disease (stages 4-5), liver disease, and severe weight loss (cachexia) were among the strongest predictors of death after TAVR in a study of older patients, with liver disease carrying over seven times the mortality risk.23Heliyon. Impact of multiple comorbidities on long-term mortality in older patients following transcatheter aortic valve replacement
The practical implication is that two 85-year-olds with identical valve measurements can have wildly different life expectancies after treatment. One who is still walking independently, cooking meals, and managing a household may do well for years. Another who is bedbound, losing weight, and dealing with organ failure in multiple systems may gain little from even a successful procedure.
Low-Flow, Low-Gradient Aortic Stenosis
Not all severe aortic stenosis looks the same on an echocardiogram. Some patients have a weakened heart muscle that cannot push enough blood through the narrowed valve to generate the high pressures you’d typically see with severe stenosis. This creates a tricky diagnostic and prognostic subcategory called low-flow, low-gradient aortic stenosis. A study following TAVR patients with this pattern found that those with a “classical” low-flow, low-gradient form (where the heart muscle is clearly weakened) initially had the worst survival of any subtype. However, after statistical adjustment for baseline differences, their long-term survival was comparable to patients with the standard high-gradient form. Patients whose heart-pumping function improved by more than ten percentage points after the procedure lived significantly longer.24PubMed Central. Long-term survival after TAVI in low-flow, low-gradient aortic valve stenosis In short, what the heart does after the procedure matters at least as much as what it was doing before.
Quality of Life After Valve Replacement
Survival numbers tell only half the story. People considering valve replacement reasonably want to know whether they will feel better, not just whether they will live longer. The evidence here is encouraging. A Dutch study found that physical functioning, energy levels, and perceived general health all improved significantly one year after aortic valve replacement.25PubMed Central. The effect of aortic valve replacement on quality of life in symptomatic patients with severe aortic stenosis A larger study of nearly 900 patients found that average physical health scores rose from 55 to 66 and mental health scores from 60 to 66 after surgery.26The Journal of Thoracic and Cardiovascular Surgery. Impact of age on quality of life after surgical aortic valve replacement
That said, not everyone improves. About 12% of patients under 65 experienced a meaningful decline in physical quality of life after surgery, and the proportion rose to 22% in those over 80.26The Journal of Thoracic and Cardiovascular Surgery. Impact of age on quality of life after surgical aortic valve replacement Starting with higher baseline function and older age both predicted a less favorable trajectory. An analysis from the PARTNER trials added that the degree of cardiac damage present before the procedure strongly predicted whether patients ended up with a good or poor outcome. Among patients with the least cardiac damage at baseline, only about 11% had a poor result (death or low quality-of-life scores) at one year, compared with roughly 40-45% of those with the most extensive damage.27PubMed. Cardiac Damage and Quality of Life After Aortic Valve Replacement in the PARTNER Trials The message for patients: the earlier the intervention happens in the course of heart damage, the better the chance of feeling genuinely good afterward.
Sex and Race Gaps in Treatment and Survival
Women with severe aortic stenosis tend to be diagnosed at older ages and with more advanced symptoms than men. Despite having more symptoms, they are less likely to receive valve replacement. A study in the Journal of the American Heart Association reported higher five-year excess mortality in women compared with men, even after matching for age.28PubMed Central. Excess Mortality and Undertreatment of Women With Severe Aortic Stenosis This disparity appears to be driven by undertreatment rather than any inherent biological disadvantage, since women who do receive valve replacement generally do at least as well as men.
Racial and ethnic disparities are equally striking. An analysis of Medicare beneficiaries from 2012 to 2019 found that Black, Hispanic, and Asian patients were all significantly less likely to undergo aortic valve replacement compared with White patients. Among emergency or urgent admissions, the gap was especially wide: about 41% of White patients received valve replacement versus roughly 30% of Black patients.29PubMed Central. Racial/Ethnic Disparities in Aortic Valve Replacement Among Medicare Beneficiaries in the United States, 2012-2019 Since untreated severe aortic stenosis carries such high mortality, disparities in access to the procedure translate directly into disparities in survival.
Mechanical Versus Bioprosthetic Valves in Younger Patients
For patients under 50 or 60 who need valve replacement, a distinct trade-off shapes life expectancy: mechanical valves last longer but require lifelong blood-thinning medication, while bioprosthetic (tissue) valves avoid the anticoagulation burden but wear out and may need to be replaced down the road. A study comparing the two in patients 50 and younger found no differences in survival, stroke, or bleeding rates, but those who received bioprosthetic valves had significantly higher rates of reoperation.30PubMed Central. Age-Specific Outcomes of Bioprosthetic vs. Mechanical Aortic Valve Replacement: Balancing Reoperation Risk with Anticoagulation Burden The choice between the two valve types does not appear to affect how long you live, but it does affect the kind of risks you take on for the rest of your life. Younger patients in particular should have a detailed conversation with their surgeon about which set of trade-offs they are more comfortable managing over decades.